Literature DB >> 17308965

Recent advances in growth hormone signaling.

Nathan J Lanning1, Christin Carter-Su.   

Abstract

Growth hormone (GH) is a major regulatory factor for overall body growth as evidenced by the height extremes in people with abnormal circulating GH levels or GH receptor (GHR) disruptions. GH also affects metabolism, cardiac and immune function, mental agility and aging. Currently, GH is being used therapeutically for a variety of clinical conditions including promotion of growth in short statured children, treatment of adults with GH deficiency and HIV-associated wasting. To help reveal previous unrecognized functions of GH, better understand the known functions of GH, and avoid adverse consequences that are often associated with exogenous GH administration, careful delineation of the molecular mechanisms whereby GH induces its diverse effects is needed. GH is a peptide hormone that is secreted into the circulation by the anterior pituitary and acts upon various target tissues expressing GHR. GH binding of GHR activates the tyrosine kinase Janus kinase 2 (JAK2), thus initiating a multitude of signaling cascades that result in a variety of biological responses including cellular proliferation, differentiation and migration, prevention of apoptosis, cytoskeletal reorganization and regulation of metabolic pathways. A number of signaling proteins and pathways activated by GH have been identified, including JAKs, signal transducers and activators of transcription (Stats), the mitogen activated protein kinase (MAPK) pathway, and the phosphatidylinositol 3'-kinase (PI3K) pathway. Although these signal transduction pathways have been well characterized, the manner by which GH activates these pathways, the downstream signals induced by these pathways, and the cross-talk with other pathways are not completely understood. Recent findings have added vital information to our understanding of these downstream signals induced by GH and mechanisms that terminate GH signaling, and identified new GH signaling proteins and pathways. This review will highlight some of these findings, many of which are unexpected and some of which challenge previously held beliefs about the mechanisms of GH signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17308965     DOI: 10.1007/s11154-007-9025-5

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   9.306


  96 in total

Review 1.  Identification of the first patient with a confirmed mutation of the JAK-STAT system.

Authors:  Ron G Rosenfeld; Eric Kofoed; Caroline Buckway; Brian Little; Katie A Woods; Junko Tsubaki; Katherine A Pratt; Liliana Bezrodnik; Hector Jasper; Alejandro Tepper; Juan J Heinrich; Vivian Hwa
Journal:  Pediatr Nephrol       Date:  2005-02-02       Impact factor: 3.714

Review 2.  The role of C/EBP genes in adipocyte differentiation.

Authors:  G J Darlington; S E Ross; O A MacDougald
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

3.  Retinal ganglion cell survival in development: mechanisms of retinal growth hormone action.

Authors:  Esmond J Sanders; Eve Parker; Steve Harvey
Journal:  Exp Eye Res       Date:  2006-08-07       Impact factor: 3.467

4.  Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.

Authors:  Jason H Kurzer; Pipsa Saharinen; Olli Silvennoinen; Christin Carter-Su
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  Gigantism in mice lacking suppressor of cytokine signalling-2.

Authors:  D Metcalf; C J Greenhalgh; E Viney; T A Willson; R Starr; N A Nicola; D J Hilton; W S Alexander
Journal:  Nature       Date:  2000-06-29       Impact factor: 49.962

6.  Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells.

Authors:  D T Lincoln; F Sinowatz; L Temmim-Baker; H I Baker; S Kölle; M J Waters
Journal:  Histochem Cell Biol       Date:  1998-02       Impact factor: 4.304

7.  Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone.

Authors:  T Yamauchi; K Ueki; K Tobe; H Tamemoto; N Sekine; M Wada; M Honjo; M Takahashi; T Takahashi; H Hirai; T Tushima; Y Akanuma; T Fujita; I Komuro; Y Yazaki; T Kadowaki
Journal:  Nature       Date:  1997-11-06       Impact factor: 49.962

8.  Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent.

Authors:  Tao Zhu; Ling Ling; Peter E Lobie
Journal:  J Biol Chem       Date:  2002-09-05       Impact factor: 5.157

9.  Grb10 identified as a potential regulator of growth hormone (GH) signaling by cloning of GH receptor target proteins.

Authors:  S Moutoussamy; F Renaudie; F Lago; P A Kelly; J Finidori
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

10.  The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH.

Authors:  L S Smit; D J Meyer; N Billestrup; G Norstedt; J Schwartz; C Carter-Su
Journal:  Mol Endocrinol       Date:  1996-05
View more
  77 in total

1.  The long noncoding RNA, EGFR-AS1, a target of GHR, increases the expression of EGFR in hepatocellular carcinoma.

Authors:  Hao-Long Qi; Chang-Sheng Li; Chong-Wei Qian; Yu-Sha Xiao; Yu-Feng Yuan; Quan-Yan Liu; Zhi-Su Liu
Journal:  Tumour Biol       Date:  2015-08-14

2.  Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver.

Authors:  Aarathi Sugathan; David J Waxman
Journal:  Mol Cell Biol       Date:  2013-07-08       Impact factor: 4.272

Review 3.  Effects of GH in human muscle and fat.

Authors:  Jens Otto Lunde Jørgensen; Kristine Z Rubeck; Thomas S Nielsen; Berthil F F Clasen; Mikkel Vendelboe; Thomas K Hafstrøm; Michael Madsen; Sten Lund
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

Review 4.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

Review 5.  Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.

Authors:  Katherine A Leehy; Thu H Truong; Laura J Mauro; Carol A Lange
Journal:  J Steroid Biochem Mol Biol       Date:  2017-04-23       Impact factor: 4.292

Review 6.  Growth hormone - past, present and future.

Authors:  Michael B Ranke; Jan M Wit
Journal:  Nat Rev Endocrinol       Date:  2018-03-16       Impact factor: 43.330

Review 7.  Somatotropic signaling: trade-offs between growth, reproductive development, and longevity.

Authors:  Andrzej Bartke; Liou Y Sun; Valter Longo
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

8.  LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice.

Authors:  Thierry Touvier; Françoise Conte-Auriol; Olivier Briand; Céline Cudejko; Réjane Paumelle; Sandrine Caron; Eric Baugé; Yves Rouillé; Jean-Pierre Salles; Bart Staels; Bernard Bailleul
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

9.  Endotoxin-induced growth hormone resistance in skeletal muscle.

Authors:  Yu Chen; Sumita Sood; Vidya M R Krishnamurthy; Peter Rotwein; Ralph Rabkin
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

Review 10.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.